Latest Content

Traws is studying an oral combination antiviral for hantavirus and Ebola, but no animal or human efficacy data have been reported.

Fluoroquinolones are broadly active and convenient, but black box warnings and resistance concerns have reshaped when and how clinicians should use them.

A 12-month longitudinal analysis of 852 children found two-thirds of those with confirmed SARS-CoV-2 infection reported at least one of 20 post-COVID symptoms, with anxiety and depression equally prevalent in uninfected peers.

Five days of nitrofurantoin was found superior to single-dose fosfomycin for uncomplicated UTI in women, prompting investigators to recommend choosing efficacy over convenience.

In the second episode with Emory’s Gavin Harris, MD, he offers some insights around treating patients with the Andes virus including supportive care as well as investigational antivirals.

Incoming SIDP President Lisa Dumkow, PharmD, FIDP, BCIDP, highlighted plans to expand mentorship, strengthen research collaboration, and move the organization's initiatives forward. She also offered insights into the new combined MAD-ID/SIDP meeting.

At the 2026 MAD-ID/SIDP meeting, Zachary Nelson, PharmD, MPH, BCIDP, discussed how urine-specific breakpoints can improve treatment decisions for urinary tract infections by accounting for drug concentrations in the urinary tract rather than relying solely on traditional blood-level interpretations.

Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses how a coalition of major medical professional societies needed to step in to sue the federal government after sweeping changes to US vaccine policy under Health and Human Services Secretary Robert F. Kennedy Jr. reshaped the CDC’s vaccine advisory process. The medical organizations argued that the evidence-based foundations of public health recommendations had been compromised.

C difficile deaths drop after 2011, but seniors, Black Americans, and rural areas still see higher mortality.

The FDA has approved bulevirtide-gmod (Hepcludex), the first approved US therapy for HPDV with no prior treatment options.

In the second episode of our conversation with David Wohl, MD, with the Institute for Global Health and Infectious Diseases at the UNC School of Medicine, he discusses the person-to person transmission, if we expect to see more cases and how it presents, including a serious complication of the virus.

A first-in-human HIV duoCAR-T shows encouraging safety in data presented at ASCGT, with early evidence of viral suppression for up to 2 years after stopping ART.

David Wohl, MD, with the Institute for Global Health and Infectious Diseases at the UNC School of Medicine, provides information on this strain, the quarantine protocols, and what the public should know about when the virus sheds and transmissibility of the disease to others.